Compare AGM & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | RCKT |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | United States |
| Employees | 212 | 202 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 534.2M |
| IPO Year | N/A | N/A |
| Metric | AGM | RCKT |
|---|---|---|
| Price | $150.87 | $4.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $215.00 | $29.65 |
| AVG Volume (30 Days) | 95.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $10.89 | $97.68 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $146.69 | $2.19 |
| 52 Week High | $210.64 | $8.80 |
| Indicator | AGM | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 33.63 | 56.97 |
| Support Level | $146.69 | $2.99 |
| Resistance Level | $164.32 | $5.34 |
| Average True Range (ATR) | 4.45 | 0.38 |
| MACD | -0.67 | 0.02 |
| Stochastic Oscillator | 4.23 | 47.90 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.